Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Valuable Targets
7 min read
New Treatment Option for Inflammatory Diseases - IRAK4 inhibitors
22 September 2023
Interleukin-1 receptor-associated kinases (IRAKs) were initially identified as serine/threonine kinases that can bind to the interleukin-1 receptor (IL-1R) upon induction by the pro-inflammatory cytokine interleukin-1 (IL-1).
Drug Insights
4 min read
Unleashing the Power of Cefpodoxime proxetil: A Comprehensive Review on R&D Breakthroughs
22 September 2023
This article summarized the latest R&D progress of Cefpodoxime proxetil, the Mechanism of Action for Cefpodoxime proxetil, and the drug target R&D trends for Cefpodoxime proxetil.
Latest Hotspot
3 min read
LinKinVax and Gustave Roussy confirmed the initiation of dosage in the Phase I/IIa HPV.DCVax clinical trial for HPV-positive Oropharyngeal Cancer
22 September 2023
LinKinVax and Gustave Roussy have reported that Gustave Roussy is treating the initial participant in a Phase I/IIa clinical trial using CD40HVac.
Drug Insights
4 min read
A Comprehensive Review of Sulfacetamide sodium's R&D Innovations and Drug Target Mechanism
22 September 2023
This article summarized the latest R&D progress of Sulfacetamide sodium, the Mechanism of Action for Sulfacetamide sodium, and the drug target R&D trends for Sulfacetamide sodium.
Valuable Targets
6 min read
Potential treatment drugs for autoimmune diseases - IL-17 inhibitors
22 September 2023
IL-17, or Interleukin-17, is a cytokine that plays a crucial role in the human body's immune response.
Drug Insights
5 min read
Pharmaceutical Insights: Sodium zirconium cyclosilicate's R&D Progress
22 September 2023
This article summarized the latest R&D progress of Sodium zirconium cyclosilicate, the Mechanism of Action for Sodium zirconium cyclosilicate, and the drug target R&D trends for Sodium zirconium cyclosilicate.
Latest Hotspot
3 min read
The FDA receives Lantern Pharma's IND, paving the way to Initiate Phase 1 trials for LP-284 in Non-Hodgkin’s Lymphomas
22 September 2023
Artificial intelligence-focused Lantern Pharma Inc unveiled the FDA's approval of their IND application for LP-284.
Drug Insights
4 min read
Exploring Rifabutin's Revolutionary R&D Successes and its Mechanism of Action on Drug Target
22 September 2023
This article summarized the latest R&D progress of Rifabutin, the Mechanism of Action for Rifabutin, and the drug target R&D trends for Rifabutin.
Valuable Targets
6 min read
Precise Therapy for Leukemia – IDH1 Inhibitors
22 September 2023
IDH includes three subtypes -IDH1, IDH2, and IDH3. Depending on the subtype, they can be monomers, homodimers, and polymers.
Drug Insights
4 min read
Decoding Pyridostigmine bromide: A Comprehensive Study of its R&D Trends
22 September 2023
This article summarized the latest R&D progress of Pyridostigmine bromide, the Mechanism of Action for Pyridostigmine bromide, and the drug target R&D trends for Pyridostigmine bromide.
Latest Hotspot
3 min read
Otsuka and Astex declare the European Commission's authorization of INAQOVI® (oral decitabine and cedazuridine) to treat myeloid leukaemia
22 September 2023
Otsuka Pharmaceutical Europe Ltd. and Astex Pharmaceuticals, Inc. announced EC's approval of INAQOVI® for treating newly diagnosed acute myeloid leukaemia in adults unfit for standard induction chemotherapy.
Drug Insights
4 min read
Deep Scientific Insights on Pramipexole dihydrochloride's R&D Progress
22 September 2023
This article summarized the latest R&D progress of Pramipexole dihydrochloride, the Mechanism of Action for Pramipexole dihydrochloride, and the drug target R&D trends for Pramipexole dihydrochloride.